NCT03563248 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03563248
Title	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Massachusetts General Hospital
Indications	pancreatic adenocarcinoma
Therapies	Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Nivolumab + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 10 of 10 entries

Facility	City	State	Zip	Country	Details
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	United States	Details
Brigham and Women's Hospital	Boston	Massachusetts	02215	United States	Details
Dana Farber Cancer Institute	Boston	Massachusetts	02215	United States	Details
Massachusetts General Hospital	Boston	Massachusetts	02214	United States	Details
MD Anderson Cancer Center	Houston	Texas	77030	United States	Details
New York University Langone Medical Center	New York	New York	10016	United States	Details
Newton Wellesley Hospital	Newton	Massachusetts	02462	United States	Details
Sibley Memorial Hospital	Washington	District of Columbia	20016	United States	Details
The Johns Hopkins Hospital	Baltimore	Maryland	21287	United States	Details
University of Colorado Cancer Center	Aurora	Colorado	80045	United States	Details

Showing 1 to 10 of 10 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03563248Clinical Trial Detail